OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

‘A new normal with chemobrain’: Experiences of the impact of chemotherapy-related cognitive deficits in long-term breast cancer survivors
Fiona Henderson, Ainslea Cross, Amy Baraniak
Health Psychology Open (2019) Vol. 6, Iss. 1, pp. 205510291983223-205510291983223
Open Access | Times Cited: 89

Showing 1-25 of 89 citing articles:

Long‐COVID syndrome‐associated brain fog and chemofog: Luteolin to the rescue
Theoharis C. Theoharides, Christos Cholevas, Konstantinos S. Polyzoidis, et al.
BioFactors (2021) Vol. 47, Iss. 2, pp. 232-241
Open Access | Times Cited: 187

Prevalence of cognitive impairment and change in patients with breast cancer: A systematic review of longitudinal studies
Aicha B. C. Dijkshoorn, Haike E. van Stralen, Maurits Sloots, et al.
Psycho-Oncology (2021) Vol. 30, Iss. 5, pp. 635-648
Open Access | Times Cited: 108

The effect of non-pharmacological interventions on cognitive function in cancer: an overview of systematic reviews
Darren Haywood, Ashley M. Henneghan, Alexandre Chan, et al.
Supportive Care in Cancer (2025) Vol. 33, Iss. 2
Open Access | Times Cited: 3

Nasal administration of mitochondria reverses chemotherapy-induced cognitive deficits
Jenolyn F. Alexander, Alexandre V. Seua, Luis D. Arroyo, et al.
Theranostics (2021) Vol. 11, Iss. 7, pp. 3109-3130
Open Access | Times Cited: 95

Berberine ameliorates doxorubicin-induced cognitive impairment (chemobrain) in rats
Fatma H. Shaker, Marwa O. El-Derany, Sara A. Wahdan, et al.
Life Sciences (2021) Vol. 269, pp. 119078-119078
Closed Access | Times Cited: 71

Psychosocial experiences of breast cancer survivors: a meta-review
King R., Lesley Stafford, Phyllis Butow, et al.
Journal of Cancer Survivorship (2023) Vol. 18, Iss. 1, pp. 84-123
Open Access | Times Cited: 22

Chemotherapy‐induced cognitive impairment in breast cancer survivors: A systematic review of studies from 2000 to 2021
Omid Amani, Mohammad Ali Mazaheri, Mona Malekzadeh, et al.
Cancer Reports (2024) Vol. 7, Iss. 2
Open Access | Times Cited: 12

Senolytic treatment alleviates doxorubicin‐induced chemobrain
Vivekananda Budamagunta, Ashok Kumar, Asha Rani, et al.
Aging Cell (2024) Vol. 23, Iss. 2
Open Access | Times Cited: 9

Pharmacological Treatment of Chemotherapy-Induced Neuropathy: A Systematic Review of Randomized Clinical Trials
Antonio Palma, César Romero Antunes Júnior, Eduardo Silva Reis Barreto, et al.
Pain Management Nursing (2025)
Closed Access | Times Cited: 1

Chemobrain: A review on mechanistic insight, targets and treatments
Vanishree Rao, Rashmi Bhushan, Priyanka Kumari, et al.
Advances in cancer research (2022), pp. 29-76
Closed Access | Times Cited: 30

Sphingosine-1-phosphate receptor 1 activation in the central nervous system drives cisplatin-induced cognitive impairment
Silvia Squillace, Michael L. Niehoff, Timothy M. Doyle, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 17
Open Access | Times Cited: 29

“Is My Brain Ever Going to Work Fully Again?”: Challenges and Needs of Cancer Survivors with Persistent Cancer-Related Cognitive Impairment
Darren Haywood, Evan Dauer, Frank D. Baughman, et al.
Cancers (2023) Vol. 15, Iss. 22, pp. 5331-5331
Open Access | Times Cited: 20

An Overview on Chemotherapy-induced Cognitive Impairment and Potential Role of Antidepressants
Ankit Das, Niraja Ranadive, Manas Kinra, et al.
Current Neuropharmacology (2020) Vol. 18, Iss. 9, pp. 838-851
Open Access | Times Cited: 46

Oncology healthcare professionals' perceptions and experiences of ‘chemobrain’ in cancer survivors and persons undergoing cancer treatment
Darren Haywood, India N. Wallace, Blake J. Lawrence, et al.
General Hospital Psychiatry (2023) Vol. 84, pp. 271-272
Closed Access | Times Cited: 15

Protocol for the Development and Initial Validation of the COG-IMPACT Tool: A Purpose-Built Unmet Needs Assessment for Cancer-Related Cognitive Impairment
Darren Haywood, Moira O’Connor, Frank D. Baughman, et al.
Methods and Protocols (2024) Vol. 7, Iss. 4, pp. 54-54
Open Access | Times Cited: 5

Changes in EEG Microstate Dynamics and Cognition Post‐Chemotherapy in People With Breast Cancer
S. Damji, Sahar Sattari, Kendra Zadravec, et al.
Brain and Behavior (2025) Vol. 15, Iss. 3
Open Access

Accounting for unmet needs resulting from cancer-related cognitive impairment
Darren Haywood, Alexandre Chan, Raymond J. Chan, et al.
Journal of Cancer Survivorship (2025)
Open Access

Targeting the Meningeal Compartment to Resolve Chemobrain and Neuropathy via Nasal Delivery of Functionalized Mitochondria
Jenolyn F. Alexander, Rajasekaran Mahalingam, Alexandre V. Seua, et al.
Advanced Healthcare Materials (2022) Vol. 11, Iss. 8
Open Access | Times Cited: 21

Young Adults’ Lived Experiences with Cancer-Related Cognitive Impairment: An Exploratory Qualitative Study
Sitara Sharma, Jennifer Brunet
Current Oncology (2023) Vol. 30, Iss. 6, pp. 5593-5614
Open Access | Times Cited: 9

Chemotherapy-Mediated Neuronal Aberration
Pradip Kumar Jaiswara, Surendra K. Shukla
Pharmaceuticals (2023) Vol. 16, Iss. 8, pp. 1165-1165
Open Access | Times Cited: 9

Page 1 - Next Page

Scroll to top